RxDoctor Payments Data

John Lansing, DO

Neurology · Albany, NYNPI 1134549918

Payments from drug & device makers

$27,085in general payments, 2019–2025

Across 60 payments — averaging $451.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$27K
  • Livanova USA, Inc.$184
  • Neurelis, Inc.$103
  • Jazz Pharmaceuticals Inc.$89
  • AbbVie$74
  • SK Life Science, Inc.$65

What the payments were for

  • Consulting fees$7203%
  • Speaking & faculty fees$23,34086%
  • Travel & lodging$1,1264%
  • Food & beverage$1,8997%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,085 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$35,910
Medicare patients
220
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam95$139,583
XcopriCenobamate54$79,049
Nurtec OdtRimegepant Sulfate49$67,108
AptiomEslicarbazepine Acetate29$66,423
VimpatLacosamide36$36,928
ValtocoDiazepam20$35,577
NayzilamMidazolam22$30,050
UbrelvyUbrogepant28$28,863
Aimovig AutoinjectorErenumab-Aooe31$25,015
Lacosamide123$24,122
Topiramate ErTopiramate13$20,971
FycompaPerampanel17$20,043
Levetiracetam205$16,922
KeppraLevetiracetam12$14,938
LamictalLamotrigine11$11,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$26,571$206,561153 claims
SK Life Science, Inc.Xcopri$65$79,04954 claims
Neurelis, Inc.Valtoco$103$35,57720 claims
AbbVieUbrelvy$74$28,86328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →